SLC5A2 and cardiovascular disorder: In addition, those with T2D and cardiovascular disease, or who are high risk for cardiovascular disease (placing them at risk for HF), should be considered for a sodium-glucose cotransporter 2 inhibitor (SGLT2i) to reduce their risk of developing HF (class 1 recommendation) [22].